Company intelligence / Profile preview

DIMEVAR

Atlanta, Georgia, United Statesdimevar.com.ec ↗

Ownership: Private
Development stage: Commercial

Overview

Dimer Pharmaceuticals leverages an innovative Oncodegenic Approach, targeting shared molecular mechanisms between cancer and neurodegenerative diseases. Its lead program focuses on MYCN-amplified pediatric tumors with Mycinib, a novel small-molecule therapeutic disrupting previously undruggable MYCN-driven pathways. This approach aims to address urgent needs in pediatric oncology while validating their scalable platform for broader applications.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculePlatform technology (Oncodegenic Approach)
Industry: Biotech

Beyond the preview

Go deeper on DIMEVAR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIMEVAR.

Explore the full profile